HCMSG - Hepatitis C Mentor & Support Group, Inc.
Search
  • About Us
    • Our Mission
    • Board of Directors
    • Medical Advisors
  • Resources
    • Corona Virus
    • Hep C Facts & Stats
    • Medications and Treatments >
      • Patient Assistance Programs
    • Reading
    • Links
  • Programs/Training
    • The Circle Model >
      • THE CIRCLE Registration
      • Group and Facilitator Guide
    • Hepatitis C Online Training
    • The Hepatitis C Education and Support Group Assistance Program
    • Healthcare Provider Training
  • Newsletter
  • Blog
  • Support Us
    • Holiday 2020
  • Contact Us

UNITED STATES TO APPROVE POTENT ORAL DRUGS FOR HEPATITIS C

11/1/2013

3 Comments

 
This
s the first time in the history of humankind that we have a cure for a viral
disease,” says pharmacologist Raymond Schinazi of Emory University in Atlanta,
Georgia.



 
Improved treatments offer hope for eradication of viral liver
infection.

Nature.com
30 October 2013



For decades, people with hepatitis C virus (HCV) have had to endure gruelling
treatment regimens that include injections of the drug interferon, which can
cause severe nausea and depression. But with the imminent approval of several
highly effective oral antiviral drugs, and more on the way, researchers say that
eradicating the infection worldwide is now a realistic goal.


Unlike previous HCV treatments, which sought to enhance the immune system with interferon and other
drugs, the latest group of oral medications interferes with the virus’s ability
to replicate and make proteins. A US Food and Drug Administration (FDA) board
recommended two such drugs — simeprevir, made by Johnson & Johnson in New
Brunswick, New Jersey, and sofosbuvir from Gilead Sciences
in Foster City, California
— for approval last week. When
each is taken in combination with a drug called ribavirin, the treatment
  eliminates hepatitis C in around 80% of people.


“This is the first time in the history of humankind that we have a cure for a viral
disease,” says pharmacologist Raymond Schinazi of Emory University in Atlanta,
Georgia.


Findings from trials of different drug combinations are set to be released this week. A
phase II study called COSMOS tested a combination of sofosbuvir and simeprevir
in 197 people with HCV who had either not responded to interferon or who had
advanced liver fibrosis caused by the virus. After 12 weeks of treatment, the
drugs completely cleared the virus in more than 90% of participants.


Another study, led by physician Kazuaki Chayama at Hiroshima University in Japan,
treated 220 people with a combination of daclatasvir and asunaprevir, two new
drugs from Bristol-Myers Squibb in New York. The cocktail cured 85% of
  participants. Eric Hughes, lead global medical researcher at the company, says
  that it plans to submit the drugs for FDA approval in 2014.


Despite such encouraging results, larger studies of drug combinations involving multiple
drug companies seem to be unlikely. Charlotte Edenius, vice-president of
development at Medivir, a drug company in Stockholm that collaborated with
Johnson & Johnson on the COSMOS study, says that Gilead and Johnson &
Johnson do not plan to work together for a phase III trial. Similarly, a
Bristol-Myers Squibb spokesperson says the company has no plans to collaborate
with Gilead on larger trials of a combined sofosbuvir–daclatasvir therapy,
despite a phase II trial completed earlier this year in which the drug pairing
cured all 41 participants.


Even without phase III trials or FDA approval for this approach, David Thomas, a
hepatitis C researcher at Johns Hopkins University in Baltimore, Maryland,
expects that some physicians will begin prescribing such combinations
  'off-label' for difficult-to-treat cases.


And, he says, the impressive cure rates achieved in clinical trials suggest that potent
drug combinations could eradicate HCV worldwide — at least in theory. The virus
does not have an animal reservoir, meaning that it is not harboured by other
animals, and it is not easily spread between people, except through blood.
Improved screening of blood supplies used for transfusions and better
  patient-screening techniques have already greatly cut transmission rates over
  the last 15 years. Emergence of drug-resistant virus strains could be a hurdle,
  adds Thomas, but they might be rare because the latest antiviral drugs are so
  potent in combination.


Price
problem

Hepatologist Rajender Reddy at the University of
Pennsylvania in Philadelphia sees a second stumbling block: getting such
treatments to people who need them. Many of the roughly 170 million people
worldwide who carry hepatitis C will not be able to afford the drugs, he says.
There is also little incentive for drug companies to lower costs — unlike
antiviral therapies for HIV, which must be taken for a patient's lifetime, HCV
treatment is given for only 12 weeks.


Identifying HCV carriers is also challenging, because most people do not know that they have the
disease until they develop severe cirrhosis or liver cancer — sometimes decades
after being infected. Mandatory screening of at-risk populations
such as the elderly and drug users would need to be a major part of an
eradication effort, says virologist Charles Rice of Rockefeller University in
New York. Crucial too is education to prevent people from contracting the
disease in the first place. Even the most effective oral drugs do not raise a
lasting immune response against the virus, and people can be reinfected.


That is why the search for a preventative HCV vaccine continues, with the most promising
ones currently in phase II clinical trials. “Even if we have all the drugs we
need — which is still an open question — it will be decades, if not a century,
before it’s gone,” says Rice.


 
3 Comments
Stephen in Alabama link
11/4/2013 12:10:37 am

I am quite interested to see what happens with the research to develop a viable vaccine for hepatitis C. It is unfortunate to learn most of the people living with this infectious disease would not be able to afford this new oral therapy, Still, it seems like we are getting closer and closer to producing 100 percent cure rates in trials, and in the end that may be the most important factor.

Reply
Robert in Cleveland link
11/12/2013 12:01:28 am

I completely agree with Charles Rice closing assertion in this post. Following the reports from the CDC last year, the prevalence of HCV is greater than many had deemed possible. The creation of a preventative vaccine could make all the difference in the world, since a large number of people are completely ignorant of the infectious disease which they carry.

Reply
essay writing services link
11/13/2013 11:40:19 am

I'm glad that the health authorities do their really best in examining and making medicines against hepatitis C. The government should also be commended in making this medical advisory possible!

Reply

Your comment will be posted after it is approved.


Leave a Reply.

    Archives

    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013
    October 2013
    September 2013
    August 2013
    July 2013
    June 2013
    May 2013
    April 2013
    March 2013
    February 2013
    January 2013
    December 2012
    November 2012
    October 2012
    September 2012
    August 2012
    July 2012
    June 2012
    May 2012
    April 2012
    March 2012
    February 2012
    January 2012
    December 2011
    November 2011
    October 2011
    September 2011
    August 2011
    July 2011
    June 2011
    May 2011

    Categories

    All

    RSS Feed

Privacy Policy